BioNTech : Annual Report 2022 with the Consolidated Financial Statements as of 31 December 2022, the Combined Management Report for BioNTech SE and the Group and the Report of the Supervisory Board for the 2022 financial year
May 02, 2024 at 08:23 pm EDT
Share
BioNTech | Annual Report 2022
2
tomorrow
BioNTech Annual Report 2022
BioNTech | Annual Report 2022
3
BioNTech | Annual Report 2022
4
DNA sequencing
FOR QUICK NAVIGATION, USE THE BUTTONS IN THE UPPER LEFT CORNER
CONTENTS SEARCH PREVIOUS PAGE
Deoxyribonucleic acid ("DNA") is the biological molecule that carries genetic information as a code. It consists of four different building blocks called nucleotides, often referred to by the first letters of their chemical names: A, T, C and G. DNA is essential for the development and functioning of living organisms.
Decoding the sequence of DNA is key to understanding the function of genes and other parts of the genome. To determine the exact sequence of nucleotides, a laboratory technique called DNA sequencing is used. There are different methods to sequence DNA. The Sanger sequencing method, which
is illustrated in the picture, has existed for approximately forty years and is widely used. The shown fluorescent bands of different colors represent the four different nucleo- tides, illustrating their position in the DNA sequence. This way, the genetic code of a cell can be determined.
Differences between DNA sequences of a patient's healthy and tumor cells are a prerequisite for creating personalized therapies tailored to the individual tumor. We at BioNTech use next-generation sequencing to identify targets for personalized mRNA-based vaccines.
BioNTech | Annual Report 2022
Our pipeline
13
MAGAZINE
Milestones 2022
36
Turning our vision into reality
09
BioNTech by the numbers
11
Our pipeline
13
Board letter
17
Report of the Supervisory Board
on the 2022 financial year
25
Milestones 2022
36
Innovative pipeline -
Platform approaches and
synergistic combinations
48
Our commitment -
to better healthcare worldwide
64
BioNTech 2.0 -
Organizational structures
for holistic growth
74
48
Innovative pipeline - Platform approaches and synergistic combinations
5
Our commitment - to better healthcare worldwide
64
BioNTech 2.0 - Organizational structures for holistic growth
Lymphocytes are a type of white blood cell that form part
of the immune system. They work together to eliminate threats. Lymphocytes include cells that can directly eliminate threats, such as Natural Killer cells and T cells. Lymphocytes also comprise B cells, which produce antibodies. Antibodies are molecules that impair the function of the pathogen or the cancer cell and mark them for elimination.
BioNTech | Annual Report 2022
Turning our vision
9
A GLOBAL
NEXT-GENERATION
IMMUNOTHERAPY COMPANY
into reality
We at BioNTech aim to strengthen and further develop our position as a global immunotherapy powerhouse. To this end, our strategy is focused on three priorities:
INNOVATIVE AND DIVERSIFIED PIPELINE
Develop potent and precise medicines to address diseases with high unmet medical needs
HEALTHCARE
INNOVATION
AND SOCIETAL
AT SCALE
RESPONSIBILITY
Contribute to democratize
Establishing and fostering
access to novel medicines
specific organizational
around the globe
structures for holistic
growth
Pipeline
Societal responsibility
Innovation at scale
The foundation for these priorities lies in our corporate values, unique culture, vision and spirit: We aspire to translate science into survival by developing new immunotherapies and vaccines utilizing the full potential of the immune system.
VISION MISSION
The foundation for our strategy are our corporate values,
unique BioNTech culture, vision and spirit.
BioNTech | Annual Report 2022
10
Attachments
Original Link
Original Document
Permalink
Disclaimer
BioNTech SE published this content on
03 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
03 May 2024 00:22:07 UTC.
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
BioNTech : Annual Report 2022 with the Consolidated Financial Statements as of 31 December 2022, the Combined Management Report for BioNTech SE and the Group and the Report of the Supervisory Board for the 2022 financial year